3 hours Cantor Fitzgerald Reaffirms Overweight Rating for ARS Pharmaceuticals (NASDAQ:SPRY) MarketBeat
Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday.
Nasdaq 100 · Pharmaceuticals · Science